Epitalon 10 mg, 50 mg and Other Forms: Vials, Capsules, Tablets and Pens

Epitalon products are often offered online in quantities such as 10 mg, 50 mg, 100 mg, or others, and may come in the form of vials, powder, capsules, tablets, sprays, or ready-to-use pens. These designations describe the amount of material or product format, but do not define a clinically validated dose of Epitalon, equivalent bioavailability, or a standardized research protocol. [1–4]

Epitalon, also known as Epithalon or Epithalone, is the tetrapeptide Ala-Glu-Asp-Gly (AEDG). The unmodified peptide has a molecular weight of approximately 390.35 g/mol. The acetate and trifluoroacetate forms contain additional counterions, which is why their total molecular weights are different.

This distinction matters when interpreting queries such as Epitalon 10 mg, Epithalon 50 mg, Epitalon 100 mg, Epitalon capsules, Epitalon tablets, or ready-to-use Epithalon pens. A higher number on the product label does not automatically mean greater potency per single administration, higher quality, better bioavailability, or greater similarity to the preparations used in published studies.

Most historical studies on Epitalon used strictly defined experimental dosages rather than contemporary commercial packaging sizes. In one recent in vitro study, 10 mg of Epitalon was used to prepare a laboratory stock solution, but the cultured cells were ultimately exposed to concentrations of only 0.1–1.0 μg/mL. [2] Therefore, a 10 mg vial should not be interpreted as an experimental dose or a human dose.

What does Epitalon 10 mg mean?

Epitalon 10 mg generally means the vial is labeled as containing a nominal total mass of 10 milligrams of Epitalon material. This does not mean 10 mg per dose, 10 mg/mL, or a clinically validated amount, as the final concentration and experimental exposure depend on the formulation, volume, content assay, route of administration, and study protocol.

It is particularly important to distinguish between mass and concentration.

A vial labeled 10 mg indicates the nominal amount of material in the container. It does not determine the concentration until the final volume of liquid is known.

It also does not confirm how much biologically active AEDG is actually present in the preparation, unless the product specification defines the chemical form and includes the appropriate content designation.

The 2025 study by Al-Dulaimi on human cells provides a good example. The researchers obtained 10 mg of Epitalon and used this amount to prepare a stock solution with a concentration of 2.5 mg/mL. This solution was then serially diluted before being added to cell cultures at final concentrations of 0.1, 0.2, 0.5, or 1.0 μg/mL. [2]

These values describe three different things:

10 mg was the initial mass used to prepare the stock solution.

2.5 mg/mL was the concentration of the stock solution.

0.1–1.0 μg/mL was the actual concentration applied to the experimental cells.

These values should not be treated as interchangeable.

The study does not establish 10 mg as a human dose or as a therapeutic cycle.

A discussion of the quantities used in research, rather than packaging designations, can be found in the article What Epithalon Dosages Have Been Reported in Research?

How does Epitalon 50 mg differ from a 10 mg vial?

An Epitalon 50 mg vial nominally contains five times the total amount of peptide material compared to a 10 mg vial, but this difference alone does not provide information about purity, final concentration, experimental dose, stability, bioavailability, or biological efficacy. Therefore, the package size must be considered separately from the research protocol in which the peptide is used.

The numerical difference is simple: a container labeled as 50 mg nominally contains five times more material than a container labeled as 10 mg.

However, scientific interpretation requires more information.

The 50 mg vial may simply contain a larger amount of the same peptide, but researchers should still determine whether the product is:

• unmodified Epitalon or another analogue;
• free peptide, acetate or another salt form;
• correctly labeled in terms of peptide content;
• chemically pure;
• lyophilized or already dissolved;
• covered by batch-specific analytical documentation.

A larger vial does not automatically mean a more concentrated solution, because the final concentration depends on how the material is prepared for the experiment.

Nor does it mean that the published studies used 50 mg doses. Classic rodent studies typically used quantities on the microgram level per animal, which is several orders of magnitude less than modern packaging labels such as 10, 50, or 100 mg. [1]

Therefore, the mass of the commercial packaging and the experimental dose should remain separate concepts.

What quantities of Epitalon appear in search data?

The search cluster provided shows interest in Epitalon 10 mg, Epithalon 50 mg, and especially Epitalon 100 mg. These search queries reflect how users search for commercially available quantities of the product, rather than evidence that any of these amounts constitutes a standardized scientific or clinical dose.

Within the keyword cluster for this article, the phrase „epitalon 100 mg” has the highest search volume among queries related to product dosage, while “10 mg” and “50 mg” also appear frequently in queries regarding package sizes.

These figures are best viewed as metrics related to commercial packaging and user behavior on search engines.

They should not be transformed into clinical claims, such as:

• 10 mg is the starting dose;
• 50 mg constitutes a complete cycle;
• 100 mg means a stronger therapeutic protocol;
• One vial size provides greater efficacy than another.

Peer-reviewed literature regarding Epitalon does not confirm such relationships.

A useful distinction is as follows:

product quantity = quantity declared on the packaging,

however

research dose = the amount or concentration intentionally used in a specific experiment.

These concepts should remain clearly separated.

What is an Epitalon Peptide Vial?

The vial containing the Epitalon peptide is simply a container holding material labeled as Epitalon, often in a dry or lyophilized form. The vial itself does not confirm the identity of the peptide, its purity, quantity, sterility, salt form, or stability. These properties require product specifications and appropriate analytical testing.

A vial is a packaging format, not a quality designation.

In peptide research, lyophilized materials are frequently supplied in vials because lyophilization can facilitate storage and handling compared to keeping certain peptides continuously in aqueous solution. However, the actual stability advantage must be determined for the specific formulation.

In the case of Epitalon, individual analytical properties should be considered separately.

Identity determines whether the material is actually AEDG.

The content designation determines how much Epitalon is in the preparation.

Purity indicates what portion of the detected material corresponds to the target peptide compared to impurities or degradation products.

The salt form or counterion indicates whether the peptide is present as free Epitalon, acetate, TFA-bound material, or another chemical form.

Sterility is a distinct microbiological characteristic and cannot be inferred based on the purity of HPLC.

Analytical confirmation is especially important in the case of Epitalon, because Vanhee and coworkers used LC-MS/MS to analyze materials labeled as Epitalon and demonstrated that mass spectrometry methods can distinguish AEDG from a very similar peptide sequence. [3]

Therefore, a designation such as „Epitalon 10 mg vial” should be treated as a product specification declaration, which ideally should be analytically confirmed.

Information on storage and preparation of the solution can be found in the article Epitalon Reconstitution, Storage and Stability for Laboratory Research.

Do Epitalon Capsules and Tablets Have Scientific Confirmation?

Epitalon was administered orally in rodent studies, but current evidence does not confirm that modern Epitalon capsules or tablets have validated human bioavailability, pharmacokinetics, clinical efficacy, or equivalence to injectable forms. Therefore, the mere availability of a capsule or tablet does not mean that a given formulation is based on confirmed clinical evidence.

There have been actual studies on oral Epitalon, but these should not be confused with the clinical validation of modern, commercially available capsules or tablets.

In studies related to Khavinson, Epithalon was administered orally to rats, and biological effects in the gastrointestinal tract were observed. These results indicate that the oral route was investigated experimentally.

However, they do not show how much intact AEDG reached the systemic circulation.

Nor do they confirm the specific capsule coating, tablet formulation, composition of excipients, release profile, or current manufacturing process.

A scientifically characterized oral formulation should ideally have evidence that the product releases chemically intact Epitalon, maintains adequate stability under gastrointestinal conditions, provides measurable systemic exposure where that is the goal, and yields a reproducible pharmacokinetic profile.

The evidence reviewed did not identify any robust human study comparing the bioavailability of Epitalon capsules and tablets.

This is important because capsules and tablets are not automatically equivalent, even in the case of conventional drugs with well-understood pharmacology. The formulation can affect the rate of release and systemic exposure, and Epitalon currently lacks human pharmacokinetic data that would allow for such comparisons.

A broader discussion can be found in the article Oral Epitalon and Sublingual Epitalon: Bioavailability and Evidence.

What is Ready Epithalon Pen?

A ready-to-use Epithalon pen would be a pre-filled device containing an Epitalon solution, designed to dispense specific doses without the need for separate preparation. However, no significant body of peer-reviewed research specific to Epitalon has been identified that would confirm its stability in the pen, the accuracy of the delivered dose, its pharmacokinetics, or its clinical equivalence with historical studies involving injections.

The term "ready-to-use pen" refers to the delivery device, not to the Epitalon molecule itself.

For approved medications, such as insulin, pens contain pre-filled solutions or suspensions and use calibrated mechanical systems to deliver specific doses.

Such a well-understood device model cannot be automatically applied to Epitalon.

A scientifically characterized pen Epitalon would require data on several distinct areas:

• peptide identity and content in solution;
• chemical stability during the stated shelf life;
• microbiological quality;
• the compatibility of the peptide with the cartridge materials;
• accuracy of the delivered volume;
• dose uniformity throughout the device's service life;
• device reliability;
• pharmacokinetics and safety specific to the route of administration.

A targeted search of the peer-reviewed literature on Epitalon did not identify any controlled trial specific to Epitalon that would validate the ready-to-use pen system.

Therefore, it should not be assumed that a pen sold as containing Epithalon is equivalent to the subcutaneous solutions used in historical animal studies just because both involve injections.

Historical studies focused on exposure to the peptide, rather than the effects of modern pen-type devices.

What is the difference between Epitalon Acetate, Epitalon TFA, and Lyophilized Powder?

Epitalon acetate and Epitalon TFA contain the same AEDG peptide sequence bound to different counterions, while „lyophilized powder” describes the physical state of the formulation, not its chemical form as a salt. These differences may affect the molecular weight, analytical calculations, formulation properties, stability, and interpretation of the declared peptide content. [1,4–6]

These terms describe different material properties.

Unmodified Epitalon

PubChem identifies Epitalon as H-Ala-Glu-Asp-Gly-OH with the molecular formula C14H22N4O9 and a molecular weight of approximately 390.35 g/mol.

A 2025 review describes the free-form version of Epitalon as the form most frequently discussed in historical literature. [1]

Epitalon Acetate

Epitalon acetate contains AEDG bound to acetic acid or acetate as a counterion.

PubChem lists Epitalon acetate as H-Ala-Glu-Asp-Gly-OH·CH3CO2H with a molecular weight of approximately 450.40 g/mol.

In July 2026, the FDA Pharmacy Compounding Advisory Committee also analyzed free-form Epitalon and Epitalon acetate as related, yet distinct active ingredients for compounding.

Examining them separately shows why their exact chemical form should be documented.

Epitalon TFA

TFA stands for trifluoroacetate, a counterion commonly encountered during the purification of synthetic peptides.

PubChem contains a separate entry for Epithalon trifluoroacetate, with a molecular weight of approximately 504.37 g/mol for the registered structure associated with TFA.

The 2025 Epitalon review also documents the use of Epitalon trifluoroacetate in at least one published experiment. [1]

General research on peptide manufacturing explains why this distinction matters. TFA can remain bound to synthetic peptides after the purification process, and pharmaceutical product development may involve exchanging the counterion from TFA to acetate. [4,5]

However, this does not mean that one Epitalon salt is clinically better than the other.

Lyophilized Epitalon

The term lyophilized describes the physical state of a product after the freeze-drying process.

The lyophilized vial may contain free Epitalon, Epitalon acetate, TFA-related material, or another validated formulation.

Therefore:

acetate/TFA = chemical counterion information,

however

lyophilized = information about the physical form of the formulation.

These are the various features of the product.

Does the Counterion Change the Amount of AEDG in a 10 mg or 50 mg Product?

Potentially yes. If the declared mass includes the entire peptide salt rather than the peptide content equivalent, the acetate or TFA increases the total molecular weight. Therefore, equal milligram amounts of different salt forms do not necessarily correspond to the same number of moles of AEDG, unless the method of content determination and the counterion specification have been clearly defined.

This is an important analytical distinction.

Unmodified Epitalon has a molecular weight of approximately 390.35 g/mol.

PubChem lists Epitalon acetate at approximately 450.40 g/mol and Epithalon TFA at approximately 504.37 g/mol for their respective registered forms.

Because counterions increase mass, equal milligram amounts of different chemical forms do not have to be molar equivalents.

However, manufacturers can declare the content in different ways. For example, a product may state the peptide equivalent itself instead of the total salt mass.

Researchers should therefore check the definition of the content label rather than draw conclusions solely from the front label.

The specifications or certificate should ideally specify whether the stated mass refers to:

• the total mass of the material;
• free peptide equivalent;
• a peptide along with its counterion;
• AEDG content adjusted based on the analysis.

Without such data, a precise comparison of the 10 mg acetate product with the 10 mg TFA product can be misleading.

What Information on the Packaging Matters in Laboratory Testing?

In laboratory testing, the Epitalon packaging should specify the peptide, nominal quantity, content or purity designation, sequence, salt form or counterion, lot number, storage requirements, expiration date or retest date, and relevant analyses. The vial size or quantity in milligrams alone is insufficient to assess the suitability of the material for testing.

The test packaging should allow for an unambiguous link between the physical material and the analytical documentation.

Important information may include:

• the product name and the peptide sequence;
• nominal mass, e.g., 10 mg, 50 mg or 100 mg;
• batch number;
• chemical form, e.g., free peptide, acetate, or TFA;
• method for determining peptide content;
• chromatographic purity;
• identity verification;
• lyophilized form or solution;
• storage conditions;
• expiry date or re-examination date;
• information on residual solvents or counterions, if relevant;
• data on sterility and endotoxins, when required by the experiment;
• documentation from the manufacturer or laboratory confirming these parameters.

Analytical testing is important because purity and identity are not the same thing.

A chromatogram may indicate that the sample is relatively homogeneous, whereas mass spectrometry or another independent analytical method can help determine whether the dominant material is indeed AEDG.

A 2015 study by Vanhee demonstrates this difference. The researchers used LC-MS/MS to identify Epitalon in the analyzed preparations and paid particular attention to the possibility of confusing it with a closely related peptide sequence. [3]

The 2025 Epitalon review also indicates that acetate and TFA forms are found in a wider range of chemical and commercial applications. [1]

For this reason, the designation „Epitalon 100 mg” constitutes incomplete scientific information if the material itself has not been properly characterized.

How Do You Compare Epitalon 10 mg, 50 mg, and 100 mg?

The quantity per package is just one of the variables.

The basic rule is that the amount in milligrams, product form, chemical form, and route of administration are separate variables.

Frequently Asked Questions About Epitalon Product Forms

What does Epitalon 100 mg mean?

Epitalon 100 mg usually refers to a product labeled as containing a nominal total mass of 100 milligrams. This does not mean that 100 mg is an evidence-based dose or a complete research cycle.

Published animal studies have often used amounts at the microgram level, and modern cell experiments have used much lower final concentrations.

Is Epitalon 50 mg stronger than Epitalon 10 mg?

The 50 mg container nominally contains more total material than the 10 mg container, but calling it „stronger” can be misleading.

Concentration, experimental dose, purity, chemical form, formulation, and route of administration are distinct variables. A larger vial does not confirm greater biological activity or clinical efficacy.

Was the Epitalon 10 mg Vial Used in Research?

Yes. In a 2025 human cell study, 10 mg of Epitalon was initially used to prepare a laboratory stock solution, but the cultured cells were ultimately exposed to only 0.1–1.0 μg/mL. [2]

Therefore, the initial amount of 10 mg should not be interpreted as a human dose.

Are Epitalon Capsules Clinically Validated?

There is currently no solid evidence confirming the clinical efficacy or absolute bioavailability of generic Epitalon capsules in humans.

Oral Epithalon has been studied in rats, but these experiments do not confirm modern capsule formulations or their equivalence to injection administration.

Are Epitalon Tablets Evidence-Based?

There is no strong clinical evidence showing that Epitalon tablets provide predictable systemic exposure or confirmed therapeutic effects in humans.

The existence of the tablet and the chemical identity of the peptide are separate issues from bioavailability and clinical efficacy.

Is Epitalon peptide scientifically validated?

No significant, peer-reviewed research base specific to Epitalon has been identified that would confirm ready-to-use pens.

A pen-type system would require a separate assessment of formulation stability, delivered dose accuracy, device performance, pharmacokinetics, and route-specific safety before it could be claimed to be equivalent to other Epitalon preparations.

Is Epitalon Acetate the Same as Epitalon?

Epitalon acetate contains the same AEDG sequence with acetate as the counterion, but it is a distinct chemical form with a different total molecular weight.

PubChem registers Epitalon and Epitalon acetate separately, and the FDA analyzed the free and acetate forms separately during its 2026 compounding review.

What is Epitalon TFA?

Epitalon TFA is Epitalon bound with trifluoroacetate.

TFA is often encountered during the production and purification of synthetic peptides, and PubChem contains Epithalon trifluoroacetate as a separate chemical entry.

Its presence should be documented, as the counterion mass and formulation properties can influence the analytical interpretation.

Does „Lyophilized” mean „Acetate”?

No.

Lyophilization refers to the freeze-drying process, whereas acetate defines the chemical counterion.

The lyophilizate may contain free Epitalon, acetate, TFA, or another formulation, depending on the manufacturing method.

Limitations of Evidence Regarding Product Forms

One of the major limitations is that commercial packaging terminology has developed much faster than the clinical evidence supporting these product forms.

Search results may include 10 mg, 50 mg, and 100 mg products, but these pack sizes were not established as standardized quantities of Epitalon in dose-ranging clinical trials.

Similarly, capsules, tablets, nasal sprays and pens may be commercially available even when there is a lack of adequate human pharmacokinetic validation.

Another limitation is the incomplete reporting of the chemical form. The same AEDG sequence can be delivered with different counterions. A 2025 review lists acetate and TFA among the forms found in the broader Epitalon literature, while the FDA in its 2026 compounding review analyzed free Epitalon and Epitalon acetate separately. [1]

An additional limitation is the fact that freeze-drying does not determine the shelf life. The stability of a specific product requires appropriate analytical testing throughout the entire declared storage time.

The mass of the packaging cannot always be treated as equivalent to the peptide content corrected based on the assay, if the salt form, amount of counterion, water content, or other formulation ingredients are not specified.

Finally, there is no scientific basis to assume that a 10 mg vial, a 100 mg vial, a capsule, a tablet, a spray, or a ready-to-use pen provide equivalent biological exposure just because each of these products is labeled as Epitalon.

Disclaimer

This article is for educational and informational purposes regarding laboratory research only. It should not be interpreted as medical advice, dosage guidelines, injection instructions, product selection recommendations, or a recommendation for the use of Epitalon.

Epitalon/Epithalon (AEDG; Ala-Glu-Asp-Gly) remains an experimental peptide, and commercial quantities such as 10 mg, 50 mg, or 100 mg do not constitute established clinical doses. It should not be assumed that capsules, tablets, pre-filled pens, lyophilized vials, acetate preparations, and TFA-related preparations provide equivalent exposure, quality, stability, or biological effects.

Researchers should rely on the specific batch analytical specification, validated laboratory procedures, and relevant institutional and regulatory requirements when evaluating Epitalon materials. Further pharmacokinetic, formulation, stability, and human clinical studies are necessary before standardized comparisons between these product forms can be established.

References

[1] Araj, S. K., Brzezik, J., Mądra-Gackowska, K., & Szeleszczuk, Ł. (2025). Overview of Epitalon—Highly bioactive pineal tetrapeptide with promising properties. International Journal of Molecular Sciences, 26(6), 2691. https://doi.org/10.3390/ijms26062691

[2] Al-Dulaimi, S., Thomas, R., Matta, S., & Roberts, T. (2025). Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology, 26(5), Article 178. https://doi.org/10.1007/s10522-025-10315-x

[3] Vanhee, C., Moens, G., Van Hoeck, E., Deconinck, E., & De Beer, J. O. (2015). Identification of the small research tetrapeptide Epitalon, assumed to be a potential treatment for cancer, old age and retinitis pigmentosa in two illegal pharmaceutical preparations. Drug Testing and Analysis, 7(3), 259–264. https://doi.org/10.1002/dta.1771

[4] Khondee, S., Wang, S. H., Kumar, R., & Dhawan, S. (2019). Formulation composition and process affect counterion for CSP7 peptide. AAPS PharmSciTech, 20. https://pubmed.ncbi.nlm.nih.gov/31569515/

[5] Araz, O., Chao, C.-M., Mo, C., et al. (2020). Oral delivery of a tetrameric tripeptide inhibitor of VEGFR1 suppresses pathological choroid neovascularization. International Journal of Molecular Sciences, 21(3), 899. https://doi.org/10.3390/ijms21030899

[6] National Center for Biotechnology Information. PubChem Compound Summary: Epitalon, CID 219042.

[7] National Center for Biotechnology Information. PubChem Compound Summary: Epitalon acetate, CID 146155988.

[8] National Center for Biotechnology Information. PubChem Compound Summary: Epithalon trifluoroacetate, CID 155977637.

[9] U.S. Food and Drug Administration. (2026). July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee: Epitalon-related bulk drug substances (Epitalon free base and Epitalon acetate).